This redundancy also may help to explain the low prevalence and penetrance of PMS2 mutations in MMR-deficient colon cancers (Lynch and de la Chapelle 2003) and the reported lack of biochemical data to support MLH3 in Lynch syndrome (Ou et al. 2009). This evidence concerns the gene PMS2 and malignant colon neoplasm.